Table 1.

Efficacy and toxicity of FDA-approved agents for advanced hepatocellular carcinoma included in the cost effectiveness analysis

Agent	Line of Therapy	Efficacy data						Toxicity data
		OS probability			PFS probability			common AE probability					discontinuation probability for toxicity
		4 mo	6 mo	12 mo	4 mo	6 mo	12 mo	HFS	fatigue	diarrhea	nausea	emesis
Placebo [3]	1	0.75	0.62	0.33	0.42	n.e.	n.e.	0.03	0.16	0.11	0.08	0.03	0.37
Sorafenib [3]	1	0.8	0.72	0.44	0.62	n.e.	n.e.	0.21	0.22	0.39	0.11	0.05	0.38
Sorafenib [12]	1	0.9	0.75	0.52	0.45	0.35	0.18	0.52	0.25	0.46	0.14	0.08	0.07
Lenvatinib [12]	1	0.9	0.82	0.58	0.65	0.55	0.32	0.27	0.3	0.39	0.2	0.16	0.09
Placebo [11]	2	0.7	0.6	0.3	0.2	0.1	0.05	0.08	0.32	0.15	0.13	0.07	0.19
Regorafenib [11]	2	0.8	0.7	0.5	0.5	0.3	0.15	0.53	0.4	0.41	0.17	0.13	0.25
Placebo [13]	2/3	0.8	0.6	0.35	0.2	0.1	0.05	0.05	0.3	0.19	0.18	0.12	0.03
Cabozantinib [13]	2/3	0.8	0.75	0.5	0.55	0.4	0.2	0.46	0.45	0.54	0.31	0.26	0.16
Nivolumab [15]	2	n.e.	0.83	n.e.	n.e.	0.37	n.e.	0.00	0.08	0.1	0.03	0.00	0.03
Pembrolizumab [14]	2	0.9	0.8	0.54	0.6	0.45	0.28	0.00	0.21	0.11	0.08	0.00	0.05

AE, adverse events; FDA, Food and Drug Administration; HFS, Hand-foot syndrome; mo, months; n.e., not evaluable; OS, overall survival; PFS, progression-free survival.